Pasar al contenido principal

La disfunción mitocondrial causada por lipoproteínas como una nueva diana terapéutica en insuficiencia cardíaca

PI24/00618

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2024
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, M.P.
Centro realización INSTITUTO DE INV. BIOMEDICAS BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced blood EPAC1 protein levels as a marker of severe Coronary Artery Disease: The role of hypoxic foam cell-transformed smooth muscle cells

  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishuck, Anna
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Piñero, Janet|||0000-0003-1244-7654
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Leta, Rubén|||0000-0003-4691-381X
  • Viladés Medel, David|||0000-0002-3638-9703
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Vascular smooth muscle cells loaded with cholesterol (foam-VSMCs) play a crucial role in the progression of human atherosclerosis. Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical protein in the regulation of vascular tone, endothelial function, and inflammation. Our objectives were to identify proteins specifically secreted by foam human coronary VSMCs (foam-hcVSMC) to evaluate their potential as circulating biomarkers for diagnosing coronary artery disease (CAD), and to ascertain the mechanisms underlying their levels in the blood of patients with CAD. Methods and Results: Differential proteomics identified EPAC1 as a differential foamhcVSMC-secreted protein. Circulating EPAC1 levels were measured by ELISA in blood from 202 patients with suspected CAD who underwent coronary computed tomography angiography (CCTA). Blood EPAC1 levels were significantly lower in CAD patients compared to controls (p < 0.001). EPAC1 levels were reduced in both men and women with severe CAD (SIS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LRP1 immunotherapy enhances cardiomyocyte respiration by restricting cholesteryl ester accumulation in mitochondria

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Garcia, E.
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishchuk, A.
  • Zegrí-Reiriz, Isabel|||0000-0001-9742-8537
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Fernández-del-Rio, L.
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
  • Samouillan, V.
  • Shirihai, Orion S.|||0000-0001-8466-3431
  • Liesa, M.
  • Enrich, Carlos|||0000-0003-0382-2993
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Antibodies (Abs) targeting the P3 sequence (Gly 1127 -Cys 1140) of LDL receptor-related protein 1 (anti-P3 Abs) inhibit the interaction between ApoB100 in cholesteryl ester (CE)-enriched lipoproteins and the CR9 domain in LDL receptor-related protein 1, preventing intracellular CE accumulation induced by a high-fat high-cholesterol (HFHC) diet in cardiomyocytes. This study examines (i) whether HFHC induces cholesterol accumulation in mitochondria, and impacts cardiac bioenergetics, and (ii) the effectiveness of anti-P3 Abs in mitigating HFHC-induced mitochondrial alterations. Cardiac tissue was homogenized, and mitochondria were isolated through subcellular fractionation. Thin layer chromatography demonstrated that HFHC induced the accumulation of CE in cardiac mitochondria, and that this process was significantly reduced by anti-P3 Abs. In line, transmission electron microscopy studies revealed that morphological changes induced by HFHC in cardiomyocyte mitochondria were reversed, at least in part, by anti-P3 Abs. Additionally, anti-P3 Abs promoted more extensive interactions between mitochondria and lipid droplets (LDs), accompanied by an increase in LD diameter and electrodensity in cardiomyocytes. Cardiac mitochondrial respiratory capacity assessed by Seahorse analysis showed that HFHC reduced CI/CIV and CII/CIV activity ratios, while anti-P3 Abs restored complex II/IV activity. In conclusion, by blocking CE uptake from lipoproteins, anti-P3 Abs reduce CE accumulation in the cardiomyocyte mitochondria and LDs, enhance bioenergetically favorable mitochondria/LD interactions, and improve cardiomyocyte respiratory function in hypercholesterolemic rabbits. These findings highlight the therapeutic potential of anti-P3 Abs in metabolic diseases by limiting CE loading of mitochondria and LDs in the heart and restoring cardiac bioenergetics.